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hospitals. The model predicts dyspnea, which is a common 
side effect of radiotherapy treatment of lung cancer.  
Materials/methods: Clinical data from 229 lung cancer 
patients, treated with curative intent with chemoradiation 
(CRT) or radiotherapy (RT) alone were collected and stored 
in 5 different medical institutes (123 patients at Maastro 
(Netherlands, Dutch), 24 at Jessa (Netherlands, Dutch), 34 at 
Liege (Belgium, Dutch and French) and 48 at Aachen 
(Germany, German)). None of the patients received 
stereotactic body radiotherapy. Patients were treated for 
their primary lung tumor and had not had another tumor in 
the 5 years before treatment.  
A Bayesian network model was trained on these data. 
Structure learning was done using the PC-algorithm at each 
hospital[1]. Network structures were transmitted to the 
central location, and using a voting algorithm, the optimal 
network structure was determined. Conditional probability 
tables were learned using the EM-learning algorithm[2]. 
Performance of the model was compared for a structure that 
was learned from multiple hospitals against a structure that 
was learned locally. The models were trained on data from 
Aachen, Liege and Jessa and validated on the data at 
Maastro. Performance was assessed using the area under 
curve (AUC) of the receiver operator characteristic. ROCs 
were compared using a method described by DeLong et al 
[3]. 
Results: The network structure of the globally learned 
Bayesian network can be observed in figure 1. The model 
performed above chance level for making predictions (AUC = 
0.69, 95% CI: 0.58-0.80). The model that used a structure 
originating from local learning also performed above chance 
level (AUC = 0.67, 95% CI: 0.55-0.79). The globally learned 
structure allows the Bayesian network to perform marginally 
better (AUC of 0.69 vs 0.67), however, this improvement is 
not significant (p = 0.69). 
Conclusions: In this work we show that it is possible to train a 
Bayesian network in a distributed setting, making a big stride 
forward to enabling personalized medicine in radiotherapy. 
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Figure 1: Network structure of the Bayesian network model. 
The Bayesian network uses, tumor location (right lower lobe, 
right middle lobe, right hilus, right upper lobe, left lower 
lobe, left upper lobe, left hilus, mediastinum), FEV1 (forced 
expiratory volume in 1 second, in %, adjusted for age and 
gender; measured prior to medication), pre-treatment 
dyspnea score (CTCAE grade < 2), baseline dyspnea score 
(CTCAE grade < 2), OTT (overall treatment time) and cardiac 
comorbidity (Non-hypertension cardiac disorder (at baseline)) 
to classify acute dyspnea. 
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Most cancer patients receive radiation therapy (RT) during 
their illness.  Virtually all RT courses are based on techniques 
and fractionation schemes determined by trial and error, 
often decades ago.  Thus there is a pressing and urgent need 
for a molecular diagnostic to inform personalized RT 
delivery.  Our team developed a molecular fingerprint of 
tumor radiosensitivity (RSI), and has subjected it to extensive 
clinical and analytical validation (1-5). RSI score distribution 
across disease sites is consistent with their known clinical 
radio-responsiveness as defined by the surviving fraction 
after 2 Gy (SF2), and has been validated in 2,200 patients in 
12 independent datasets across several disease sites. We 
have shown that RSI correlates with outcome only in patients 
treated with RT; it is not prognostic but predictive.  The 
National Cancer Institute designed the Clinical Assay 
Development Program (CADP) to assist with the development 
of assays that may predict therapy response or prognostic 
behavior of a diagnosed cancer; RSI has undergone further 
development through CADP.  
Using RSI and the linear quadratic model, our team next 
modeled the genomically adjusted dose (GAD) to predict RT 
dose effect at the individual patient level.  RSI/GAD has 
predicted cancer cohorts that will specifically benefit from 
RT-dose escalation, such as radioresistant luminal lesions in 
breast cancer (6) and some glioblastomas (7). Current data 
have also revealed that metastatic lesions have markedly 
different RSI than the primary lesion, which is further 
modified by the site of metastasis (8).  
We will discuss current knowledge of RSI/GAD and describe 
ongoing current research plans to incorporate RSI, as a 
predictive biomarker of radiosensitivity, into personalized 
therapy options for RT patients.   
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